|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of respiratory indications, one of which is asthma. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of nephrology indications, one of which is chronic kidney disease. [Read More]
|
|
|
|
|
|
|
PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is colorectal cancer. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of infectious disease indications, one of which is complicated skin & skin structure infections. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of auto-immune indications, one of which is gout. [Read More]
|
|
|
|
|
|
|
PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous hematology indications. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of infectious disease indications, one of which is hepatitis. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of infectious disease indications, one of which is HAP/VAP pneumonia. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of cardiovascular disease indications, one of which is intermittment claudication. [Read More]
|
|
|
|
|
|
|
PSI focus on predictable patient enrollment across a variety of therapeutic areas. This includes a variety of CNS indications, one of which is multiple sclerosis. Clinical trials in this area require diligence and accuracy to recruit patients on time. [Read More]
|
|
|
|
|
|
|
PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is lung cancer. [Read More]
|
|
|
|
|
|
|
PSI is known for accurate, predicable patient enrollment on-time or ahead of schedule. This includes a variety of CNS indications, one of which is opioid dependence. [Read More]
|
|
|
|
|
|
|
PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is pancreatic cancer. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of central nervous system (CNS) indications, one of which is Parkinson’s Dementia. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of cardiovascular disease indications, one of which is peripheral arterial disease. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of indications in pediatric patients that PSI has successful conducted , one of which was in Post Operative Nausea & Vomitting. [Read More]
|
|
|
|
|
|
|
PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is prostate cancer. [Read More]
|
|
|
|
|
|
|
PSI’s core strength is to predictably enroll patients across multiple therapeutic areas predictably and on-time. Previous PSI clinical trial successes include a range and depth of oncology indications, including renal cell cancer. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of auto-immune indications, one of which is rheumatoid arthritis. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of CNS indications, one of which is schizophrenia. [Read More]
|
|
|
|
|
|
|
One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of auto-immune indications, one of which is ulcerative colitis. [Read More]
|
|
|
|
|
|
|
This case study is an illustration of how operational cohesion of two research organizations – The Vienna Challenge Chamber (VCC) and PSI – translates into swift progress and predictable timelines. [Read More]
|
|
|
|
|
|
|
Early-phase clinical research in the area of respiratory tract disorders – such as asthma, allergic rhinitis (hay fever) and other atopic conditions – often warrants the use of specialized facilities. [Read More]
|
|
|
|
|
